)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Magle Chemoswed
Magle Chemoswed (MAGLE) investor relations material
Magle Chemoswed has been delisted
Magle Chemoswed Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 net sales were SEK 70.9m; EBIT was SEK -45.0m and net result after tax SEK -107.1m, with results affected by non-recurring items.
Directed share issues, set-off issues and bond refinancing increased equity and cash; liabilities to credit institutions were repaid.
Financial highlights
Q3 net sales SEK 70.9m vs SEK 71.5m; 9M net sales SEK 212.4m vs SEK 205.2m, up 3.5%.
Q3 EBIT SEK -45.0m vs SEK 20.3m; EBITDA SEK -31.1m vs SEK 33.4m; net result after tax SEK -107.1m vs SEK 3.1m.
9M EBIT SEK -75.8m vs SEK -6.6m; EBITDA SEK -36.1m vs SEK 31.6m; net result after tax SEK -146.1m vs SEK -25.8m.
Key financial ratios and metrics
Cash and cash equivalents were SEK 38.7m at Sep 30, 2026, vs SEK 2.1m at Jun 30, 2026.
Shareholders’ equity was SEK 320.4m; equity ratio 38.0% vs 36.5% at Dec 31, 2025.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Magle Chemoswed
- Revenue up but losses and tight liquidity persist; recapitalization and delisting planned.MAGLE
Q2 2026 - Revenue fell and losses deepened in Q1 2026 amid restructuring and operational challenges.MAGLEQ1 2026
- Major asset write-downs and negative results in Q4 2025 prompt capital raises and restructuring.MAGLEQ4 2025
- Q3 2025 delivered stronger EBITDA and integration progress, offset by Biopharma market weakness.MAGLEQ3 2025
- Revenue up but profitability down in Q2 2025; integration and supply chain issues impacted results.MAGLEQ2 2025
- Strong Q3 growth driven by mergers, robust CDMO demand, and one-off PPA income.MAGLEQ3 2024
- Q2 sales up 17% as Magle Group advances major mergers to drive future growth.MAGLEQ2 2024
- Q1 2025 revenue surged, but integration costs led to a net loss as acquisitions drive future growth.MAGLEQ1 2025
- Strong revenue growth and strategic acquisitions drive Magle Group's 2024 performance.MAGLEQ4 2024
Magle Chemoswed
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Magle Chemoswed Holding AB is a company active in the pharmaceutical and medical device industries, serving as a contract development and manufacturing organization (CDMO). The company is dedicated to offering a wide range of services from development through manufacturing on a contract basis, excelling in bringing innovations from idea to product. Magle Chemoswed operates through its subsidiaries, including Magle Chemoswed AB and Adroit Science AB, focusing on the process development and manufacturing of Active Pharmaceutical Ingredients (API) and the development and manufacturing of products in wound care and diagnostics, particularly those based on degradable starch microspheres. Additionally, it provides consultancy in material characterization and solid-phase analysis, mainly targeting pharmaceutical companies. The company is headquartered in Malmö, Sweden, and its shares are listed on the Nasdaq Stockholm.